Patents Represented by Attorney, Agent or Law Firm Mark R. Daniel
  • SRC kinase inhibitor compounds
    Patent number: 6329380
    Abstract: Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of proteins tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogensis, atheroscelerosis, graft rejection, rheumatoid arthritis and psoriasis.
    Type: Grant
    Filed: June 26, 2000
    Date of Patent: December 11, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Joung L. Goulet, Mark A. Holmes, Julianne A. Hunt, Sander G. Mills, William H. Parsons, Peter J. Sinclair, Dennis M. Zaller
  • SRC kinase inhibitor compounds
    Patent number: 6316444
    Abstract: Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of protein tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogensis, atheroscelerosis, graft rejection, rheumatoid arthritis and psoriasis.
    Type: Grant
    Filed: June 26, 2000
    Date of Patent: November 13, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Julianne A. Hunt, Sander G. Mills, Peter J. Sinclair, Dennis M. Zaller
  • Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a &bgr;-adrenergic antagonist
    Patent number: 6316443
    Abstract: Combinations of a &bgr;-adrenergic antagonist and a topical carbonic anhydrase inhibitor are particularly useful in the treatment of ocular hypertension, especially in patients insufficiently responsive to treatment with &bgr;-adrenergic antagonists.
    Type: Grant
    Filed: March 22, 2000
    Date of Patent: November 13, 2001
    Assignee: Merck & Co., Inc.
    Inventor: John J. Baldwin
  • Antibiotic compound
    Patent number: 6316488
    Abstract: Fermentation of a nutrient medium with a eubacterium pseudomonas sp.
    Type: Grant
    Filed: June 7, 2000
    Date of Patent: November 13, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Aurora M. Bernard-King, Michael J. Salvatore, Jr., Athanasios Tsipouras, Kennth E. Wilson
  • Inhibitors of prenyl-protein transferase
    Patent number: 6316436
    Abstract: The present invention is directed to compounds which inhibit prenyl-protein transferase and particularly, the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: December 7, 1999
    Date of Patent: November 13, 2001
    Assignee: Merck & Co., Inc.
    Inventors: S. Jane deSolms, Anthony W. Shaw
  • Tyrosine kinase inhibitors
    Patent number: 6313138
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: February 20, 2001
    Date of Patent: November 6, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, George D. Hartman, Randall W. Hartman
  • Halophenoxy substituted carbapenem antibacterial compounds
    Patent number: 6310055
    Abstract: The present invention relates to carbapenem antibacterial agents in which the carbapenem nucleus is substituted at the 2 -position with a iodophenoxy linked through a group —Z—CH2—; The compound is further substituted with various substituent groups including at least one cationic group. The compounds are represented by formula I: wherein Z represents trans-ethenediyl or ethynediyl. Pharmaceutical compositions and methods of use are also included.
    Type: Grant
    Filed: May 13, 1999
    Date of Patent: October 30, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Frank P. Dininno, Kevin D. Dykstra
  • Tyrosine kinase inhibitors
    Patent number: 6306874
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: October 17, 2000
    Date of Patent: October 23, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, Kenneth L. Arrington, Mark T. Bilodeau, George D. Hartman, William F. Hoffman, Yuntae Kim, Randall W. Hungate
  • Heterocyclic potassium channel inhibitors
    Patent number: 6303637
    Abstract: The present invention relates to a class of heterocyclic compounds of Formula I that are useful as potassium channel inhibitors to treat autoimmune disorders, cardiac arrhythmias, and the like.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: October 16, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Jianming Bao, Andrew Kotliar, Frank Kayser, William H. Parsons, Kathleen M. Rupprecht, Christopher F. Claiborne, David A. Claremon, Nigel Liverton, Wayne J. Thompson
  • Method for decreasing QT dispersion or inhibiting the progression of QT dispersion with an angiotensin II receptor antagonist
    Patent number: 6300356
    Abstract: Angiotensin II receptor antagonists are useful for decreasing QT dispersion or inhibiting the progression of QT prolongation in patients. Also disclosed is a method for monitoring the reduction in die risk of experiencing an adverse cardiac event, such as sudden cardiac death, myocardial infarction or arrhythmias, using QT dispersion in patients treated with a therapeutically effective amount of an angiotensin II antagonist.
    Type: Grant
    Filed: August 10, 2000
    Date of Patent: October 9, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Robert Segal, Paul J. Robinson, Lawrence I. Deckelbaum
  • Stabilized carbapenem antibiotic compositions and method of making
    Patent number: 6297231
    Abstract: The present invention relates to a novel stabilized form of carbapenem antibiotics of formula II: compositions and methods thereof wherein the antibiotics and compositions are stabilized degradation and dimer formation. The compounds can be used in the treatment of infectious diseases, including gram positive and negative, aerobic and anaerobic bacteria. The compounds provide good stability against beta-lactamases, and a favorable duration of action. The compounds of this invention are represented structural formula I: or a pharmaceutically acceptable or hydrate thereof.
    Type: Grant
    Filed: April 6, 1999
    Date of Patent: October 2, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Orn Almarsson, Michael J. Kaufman, John D. Stong, John M. Williams
  • Inhibitors of prenyl-protein transferase
    Patent number: 6297239
    Abstract: The present invention is directed to compounds which inhibit a prenyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting a prenyl-protein transferase and the prenylation of the oncogene protein Ras.
    Type: Grant
    Filed: October 6, 1998
    Date of Patent: October 2, 2001
    Assignee: Merck & Co., Inc.
    Inventors: S. Jane deSolms, John H. Hutchinson, Anthony W. Shaw, Samuel L. Graham, Terrence M. Ciccarone
  • Carbapenem antibacterial compounds, compositions containing such compounds and method of treatment
    Patent number: 6294528
    Abstract: Compounds of formula I: as well as pharmaceutically acceptable salts therefor and compositions useful as carbapenem antibacterial agents are disclosed.
    Type: Grant
    Filed: June 23, 1999
    Date of Patent: September 25, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Timothy A. Blizzard, Robert R. Wilkening, Ronald W. Ratcliffe
  • Method of continuously monitoring controlled temperature units
    Patent number: 6293699
    Abstract: There is disclosed a method for continuously monitoring temperature at multiple locations within a controlled temperature unit (CTU) using RTDs that can be removed and reinserted. The key to the method is the collection of data using an RTD fixed in a phenolic thermowell, which in turn is inserted through a polytetrafluoroethylene-coated sleeve in the wall of the CTU. The temperature information is transmitted from a data module to an interfaced computer system where it may be presented to the operator in a graphical, tabular or text format or stored in memory. The temperature probes are easily removable so as to facilitate calibration without disruption of the contents of the CTU and can be consistently replaced in the same location within the CTU.
    Type: Grant
    Filed: October 26, 1999
    Date of Patent: September 25, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Fred J. Bailey, Mark Pinder, Carl W. Holz
  • Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment
    Patent number: 6294529
    Abstract: Compounds of formula I are disclosed. as well as pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: October 7, 1999
    Date of Patent: September 25, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Lovji D. Cama, Ronald W. Ratcliffe, Robert R. Wilkening, Kenneth J. Wildonger, Wanying Sun
  • Carbapenem antibacterial compounds, compositions containing such compounds and method of treatment
    Patent number: 6291448
    Abstract: Compounds of formula I: as well as pharmaceutically acceptable salts thereof useful as carbapenam antibacterial agents are disclosed wherein X is CR2R2, NR2, or O.
    Type: Grant
    Filed: June 23, 1999
    Date of Patent: September 18, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Timothy A. Blizzard, Robert R. Wilkening, Ronald W. Ratcliffe
  • 6-azaindole compounds as antagonists of gonadotropin releasing hormone
    Patent number: 6288078
    Abstract: There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.
    Type: Grant
    Filed: March 7, 2000
    Date of Patent: September 11, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Thomas F. Walsh, Feroze Ujjainwalla
  • Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment
    Patent number: 6288054
    Abstract: The present invention relates to tricyclic carbapenem antibacterial agents in which the carbapenem nucleus is fused to a 6 membered carbocyclic ring. The compound is further substituted with various substituent groups including at least one cationic group. The compounds are represented by formula I: Pharmaceutical compositions and methods of use are also included.
    Type: Grant
    Filed: May 24, 1999
    Date of Patent: September 11, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Frank P. Dininno, Milton L. Hammond, Kevin D. Dykstra
  • Inhibitors of prenyl-protein transferase
    Patent number: 6284755
    Abstract: The present invention is directed to azepan-2-one compounds which inhibit prenyl-protein transferase, particularly farnesyl-protein transferase (Ftase), and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.
    Type: Grant
    Filed: December 7, 1999
    Date of Patent: September 4, 2001
    Assignee: Merck & Co., Inc.
    Inventors: S. Jane deSolms, Samuel L. Graham, Anthony W. Shaw, Terrence M. Ciccarone, Gerald E. Stokker
  • Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment
    Patent number: 6284753
    Abstract: The present invention relates to tricyclic carbapenem antibacterial agents wherein X is CH2, CHRa, CHRb, C═CHRa, C═CHRb, O, S, SO, SO2, CO, COO<OCO, NRa, NRb; and Z is trans-ethenediyl or ethynediyl. The compound is further substituted with various substituent groups including at least one cationic group. The compounds are represented by formula I: Pharmaceutical compositions and methods of use are also included.
    Type: Grant
    Filed: May 24, 1999
    Date of Patent: September 4, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Frank P. Dininno, Kevin D. Dykstra